ALMUS

Welcome to the Brand page for “ALMUS”, which is offered here for Pharmaceutical preparations for use in the treatment of crohn's disease, ulcerative colitis, severe eczema, myasthenia gravis and transplant rejection; pharmaceutical preparations to treat the gastrointestinal system, the cardiovascular system, the respiratory system, the central nervous system, infection, the endocrine system, the urinary tract, blood, musculoskeletal and joint disease, eye, ear, nose and oropharynx, skin, and malignant disease, malignant disease being defined as acute lymphoblastic leukaemia, hodgkin's disease, non-hodgkins lymphomas and other oncological diseases; pharmaceutical preparations for use in nutrition namely for the treatment and prevention of scurvy or for the treatment of vitamin b deficiency; immunosuppressants and immunological products, products to treat autoimmune conditions such as crohn's disease, ulcerative colitis, severe eczema, myasthenia gravis and transplant rejection;the term almus is latin and means life-giving and nourishing.;medical services; advisory and consultation services relating to pharmaceutical and veterinary preparations; advisory and consultation services relating to medical conditions and diseases and the treatment thereof;.

Its status is currently believed to be active. Its class is unavailable. “ALMUS” is believed to be currently owned by “Alliance UniChem Plc”.